J Clin Pathol-2014-Wong-jclinpath-2014-202467.pdf (914.12 kB)
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
journal contribution
posted on 2014-07-07, 10:18 authored by Wong NACS, Gonzalez D, Salto-Tellez M, Butler R, Salvador J. Diaz-CanoSalvador J. Diaz-Cano, Ilyas M, Newman W, Shaw E, Taniere P, Walsh SVAnalysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of antiepidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.
History
Usage metrics
Categories
- Pathology (excl. oral pathology)
- Oral medicine and pathology
- Other biomedical and clinical sciences not elsewhere classified
- Oncology and carcinogenesis not elsewhere classified
- Bioinformatic methods development
- Bioinformatics and computational biology not elsewhere classified
- Other biological sciences not elsewhere classified
- Medical biotechnology not elsewhere classified
- Biochemistry and cell biology not elsewhere classified
- Genetics not elsewhere classified
Keywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC